Current Assets
Short- term Investments
Regeneron Pharmaceuticals Short- term Investments increased by 5.5% to $5.79B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.1%, from $5.26B to $5.79B. Over 5 years (FY 2020 to FY 2025), Short- term Investments shows an upward trend with a 31.5% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
First reportedQ3 2025
Last reportedQ1 2026
Metric ID:
current_assets_marketable_securities_currentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.84B | $2.36B | $2.81B | $3.70B | $4.17B | $3.53B | $4.64B | $5.04B | $6.99B | $7.76B | $8.11B | $7.92B | $7.89B | $7.78B | $6.52B | $5.26B | $5.47B | $5.94B | $5.49B | $5.79B |
| QoQ Change | — | +28.1% | +19.3% | +31.9% | +12.6% | -15.4% | +31.3% | +8.8% | +38.6% | +11.0% | +4.6% | -2.4% | -0.4% | -1.3% | -16.2% | -19.4% | +4.1% | +8.5% | -7.6% | +5.5% |
| YoY Change | — | — | — | — | +126.9% | +49.9% | +65.0% | +36.1% | +67.6% | +119.8% | +75.0% | +57.0% | +12.8% | +0.3% | -19.6% | -33.6% | -30.6% | -23.7% | -15.9% | +10.1% |
Range$1.84B – $8.11B
CAGR+27.3%
Avg YoY Growth+31.1%
Median YoY Growth+24.5%
Short- term Investments at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's short- term investments?
- Regeneron Pharmaceuticals (REGN) reported short- term investments of $5.79B in Q1 2026.
- How has Regeneron Pharmaceuticals's short- term investments changed year-over-year?
- Regeneron Pharmaceuticals's short- term investments increased by 10.1% year-over-year, from $5.26B to $5.79B.
- What is the long-term trend for Regeneron Pharmaceuticals's short- term investments?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's short- term investments has grown at a 31.5% compound annual growth rate (CAGR), from $1.39B to $5.49B.